Longzheng Xia

4.3k total citations · 3 hit papers
43 papers, 2.7k citations indexed

About

Longzheng Xia is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Longzheng Xia has authored 43 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 24 papers in Cancer Research and 7 papers in Oncology. Recurrent topics in Longzheng Xia's work include RNA modifications and cancer (12 papers), Cancer-related molecular mechanisms research (11 papers) and Cancer, Hypoxia, and Metabolism (7 papers). Longzheng Xia is often cited by papers focused on RNA modifications and cancer (12 papers), Cancer-related molecular mechanisms research (11 papers) and Cancer, Hypoxia, and Metabolism (7 papers). Longzheng Xia collaborates with scholars based in China, United States and Uganda. Longzheng Xia's co-authors include Linda Oyang, Yujuan Zhou, Shiming Tan, Qianjin Liao, Min Su, Jinguan Lin, Yanyan Tang, Yaqian Han, Xia Luo and Jiaxin Liang and has published in prestigious journals such as Oncogene, Molecular Cancer and Journal of Hematology & Oncology.

In The Last Decade

Longzheng Xia

42 papers receiving 2.7k citations

Hit Papers

The cancer metabolic reprogramming and immune response 2021 2026 2022 2024 2021 2023 2024 250 500 750

Peers

Longzheng Xia
Min Su China
Min Xiao China
Kezuo Hou China
Ling‐Wen Ding Singapore
Xin Dong China
Longzheng Xia
Citations per year, relative to Longzheng Xia Longzheng Xia (= 1×) peers Linda Oyang

Countries citing papers authored by Longzheng Xia

Since Specialization
Citations

This map shows the geographic impact of Longzheng Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Longzheng Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Longzheng Xia more than expected).

Fields of papers citing papers by Longzheng Xia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Longzheng Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Longzheng Xia. The network helps show where Longzheng Xia may publish in the future.

Co-authorship network of co-authors of Longzheng Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Longzheng Xia. A scholar is included among the top collaborators of Longzheng Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Longzheng Xia. Longzheng Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tang, Haoneng, Peng Qiu, Linda Oyang, et al.. (2025). Fusion genes in cancers: Biogenesis, functions, and therapeutic implications. Genes & Diseases. 12(5). 101536–101536.
2.
Qiu, Peng, Lujuan Wang, Ying Long, et al.. (2025). SRSF9 mediates oncogenic RNA splicing of SLC37A4 via liquid–liquid phase separation to promote oral cancer progression. Journal of Advanced Research. 79. 505–520. 3 indexed citations
3.
Qiu, Peng, Xuemeng Xu, Wenlong Zhang, et al.. (2025). Crosstalk between RNA-binding proteins and non-coding RNAs in tumors: molecular mechanisms, and clinical significance. International Journal of Biological Sciences. 21(7). 2991–3010. 3 indexed citations
4.
Tan, Shiming, Shizhen Li, Longzheng Xia, et al.. (2025). Long non‑coding RNA ABHD11‑AS1 inhibits colorectal cancer progression through interacting with EGFR to suppress the EGFR/ERK signaling pathway. International Journal of Oncology. 66(3). 1 indexed citations
5.
Han, Yaqian, Shizhen Li, Linda Oyang, et al.. (2025). Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential. Cellular Oncology. 48(5). 1219–1244. 1 indexed citations
6.
Wang, Jiewen, Mingjing Peng, Linda Oyang, et al.. (2025). Mechanism and application of lactylation in cancers. Cell & Bioscience. 15(1). 76–76. 4 indexed citations
7.
Jiang, Xianjie, Qiu Peng, Mingjing Peng, et al.. (2024). Cellular metabolism: A key player in cancer ferroptosis. Cancer Communications. 44(2). 185–204. 36 indexed citations
8.
Jiang, Xianjie, Mingjing Peng, Qiang Liu, et al.. (2024). Circular RNA hsa_circ_0000467 promotes colorectal cancer progression by promoting eIF4A3-mediated c-Myc translation. Molecular Cancer. 23(1). 151–151. 13 indexed citations
9.
Zhang, Wenlong, Yidan Shi, Linda Oyang, et al.. (2024). Endoplasmic reticulum stress—a key guardian in cancer. Cell Death Discovery. 10(1). 343–343. 62 indexed citations breakdown →
10.
Xia, Longzheng, Jinguan Lin, Mingjing Peng, et al.. (2024). Diallyl disulfide induces DNA damage and growth inhibition in colorectal cancer cells by promoting POU2F1 ubiquitination. International Journal of Biological Sciences. 20(4). 1125–1141. 8 indexed citations
11.
Xu, Xuemeng, Qiu Peng, Xianjie Jiang, et al.. (2024). Altered glycosylation in cancer: molecular functions and therapeutic potential. Cancer Communications. 44(11). 1316–1336. 39 indexed citations
12.
Li, Shizhen, Mingjing Peng, Shiming Tan, et al.. (2024). The roles and molecular mechanisms of non-coding RNA in cancer metabolic reprogramming. Cancer Cell International. 24(1). 37–37. 15 indexed citations
13.
Xu, Xuemeng, Peng Qiu, Xianjie Jiang, et al.. (2023). Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Experimental & Molecular Medicine. 55(7). 1357–1370. 121 indexed citations breakdown →
14.
Qiu, Peng, Shiming Tan, Longzheng Xia, et al.. (2022). Phase separation in Cancer: From the Impacts and Mechanisms to Treatment potentials. International Journal of Biological Sciences. 18(13). 5103–5122. 37 indexed citations
15.
Chen, Yongchang, Lu Liu, Longzheng Xia, et al.. (2022). TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation. Journal of Experimental & Clinical Cancer Research. 41(1). 44–44. 58 indexed citations
16.
Rao, Shan, Linda Oyang, Jiaxin Liang, et al.. (2021). Biological Function of HYOU1 in Tumors and Other Diseases. OncoTargets and Therapy. Volume 14. 1727–1735. 33 indexed citations
17.
Huang, Liang, Tao Dai, Longzheng Xia, et al.. (2021). SQLE Mediates Metabolic Reprogramming to Promote LN Metastasis in Castration-Resistant Prostate Cancer. OncoTargets and Therapy. Volume 14. 4285–4295. 14 indexed citations
18.
Tan, Shiming, Pin Yi, Heran Wang, et al.. (2020). RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer. Frontiers in Oncology. 10. 649–649. 21 indexed citations
19.
Su, Min, Heran Wang, Wenxiang Wang, et al.. (2018). LncRNAs in DNA damage response and repair in cancer cells. Acta Biochimica et Biophysica Sinica. 50(5). 433–439. 50 indexed citations
20.
Xia, Longzheng, Shiming Tan, Yujuan Zhou, et al.. (2018). Role of the NFκB-signaling pathway in cancer. OncoTargets and Therapy. Volume 11. 2063–2073. 345 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026